| Title | Author(s) | Year | View Count |
 | Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B | Gish, RG; Chang, TT; Lai, CL; De Man, R; Gadano, A; Poordad, F; Yang, J; BrettSmith, H; Tamez, R | 2010 | 312 |
 | Three-year assessment of entecavir resistance in chronic hepatitis B patients and the mechanism of viral breakthrough by the resistance substitutions | Tanaka, Y; Mukaide, M; Yuen, RMF; Shin, IT; Orito, E; Kurbanov, F; Fukai, K; Yokosuka, O; Sata, M; Ide, T; Karino, Y; Yamada, G; Sakaguchi, K; Inoue, M; Gish, RG; Lai, CL; Mizokami, M | 2008 | 180 |
| T1653 mutation in the box α increases the risk of hepatocellular carcinoma in patients with chronic hepatitis B virus genotype C Infection | Ito, K; Tanaka, Y; Orito, E; Sugiyama, M; Fujiwara, K; Sugauchi, F; Kato, T; Tokita, H; Izumi, N; Kato, M; Yuen, MF; Lai, CL; Gish, RG; Ueda, R; Mizokemi, M | 2006 | 47 |
| Epidemiologic and virologic characteristics of hepatitis B virus genotype B having the recombination with genotype C | Sugauchi, F; Orito, E; Ichida, T; Kato, H; Sakugawa, H; Kakumu, S; Ishida, T; Chutaputti, A; Lai, CL; Gish, RG; Ueda, R; Miyakawa, Y; Mizokami, M | 2003 | 106 |
|
